Antibodies specific to ABCB5 and uses thereof

WO2026112432A8PCT designated stage Publication Date: 2026-07-02CHILDRENS MEDICAL CENT CORP +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
CHILDRENS MEDICAL CENT CORP
Filing Date
2025-11-21
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

Current therapies for cancer, particularly those targeting ABCB5+ tumor cells, face challenges due to drug resistance mediated by the ABCB5 transporter, which confers resistance to chemotherapeutic agents and limits treatment efficacy.

Method used

Development of antibodies specifically binding to ATP-binding cassette transporter family member B5 (ABCB5) with enhanced binding affinity and specificity, capable of inducing antibody-dependent cellular cytotoxicity, phagocytosis, and inhibiting signal transduction processes, as well as their use in antibody-drug conjugates and chimeric antigen receptor (CAR)-modified immune cells to target ABCB5+ cells.

Benefits of technology

The antibodies effectively reduce tumor growth and enhance treatment outcomes by specifically targeting ABCB5+ cells, overcoming drug resistance and enhancing immune response against cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025056569_02072026_PF_FP_ABST
    Figure US2025056569_02072026_PF_FP_ABST
Patent Text Reader

Abstract

Anti-ABCB5 antibodies and related compositions including the antibodies for binding the extracellular loop of ABCB5 are disclosed. The antibodies are useful for therapeutic methods such as methods of treating cancer, diagnostic methods and research / manufacturing for isolating and purifying ABCB5+ stem cells.
Need to check novelty before this filing date? Find Prior Art